mayne pharma: Live & Latest News Updates : Vimarsana.com

TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Free Report) in a research note released on Thursday. The firm issued a hold rating on the stock. TherapeuticsMD Trading Down 0.5 % Shares of TXMD opened at $1.86 on Thursday. The stock has a fifty day moving average of $2.22 and a two-hundred day moving […]

Highest-paid CFOs revealed

The country’s top CFOs continue to enjoy a “breakout period” on pay and remain in the box seat as the country’s next CEOs.

Super Generics Market Size Will Reach USD 128.62 Billion to 2031 - Revealed InsightAce Latest Study

/PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Super Generics Market –By Therapeutic Area...

Favourable Signals For Mayne Pharma Group: Numerous Insiders Acquired Stock

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

Lupin gets target hike from Nomura to Rs 1,949 on growth potential in US products

Nomura suggests that the launch of US products and stringent cost control measures could exceed current earnings estimates. Additionally, Lupin has potential limited competition opportunities in FY25 with products like gOracea, gMyrbetriq, and gSlynd, pending a favorable verdict.

Analysts' Weekly Ratings Changes for TherapeuticsMD (TXMD)

StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Free Report) in a research report sent to investors on Monday. The firm issued a hold rating on the stock. TherapeuticsMD Trading Down 0.9 % TherapeuticsMD stock opened at $2.23 on Monday. The business’s 50-day simple moving average is $2.31 and its two-hundred day simple moving […]

TherapeuticsMD Announces Full Year 2023 Financial Results

• Evaluation of strategic alternatives continues ...

TherapeuticsMD Announces Full Year 2023 Financial Results

TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com